Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL trimmed its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 18.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 105,600 shares of the company’s stock after selling 24,100 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Teva Pharmaceutical Industries were worth $2,327,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TEVA. Stifel Financial Corp raised its holdings in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after buying an additional 23,283 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $198,000. Barclays PLC grew its stake in shares of Teva Pharmaceutical Industries by 31.7% in the 3rd quarter. Barclays PLC now owns 427,595 shares of the company’s stock valued at $7,705,000 after purchasing an additional 102,848 shares during the last quarter. Sanctuary Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after purchasing an additional 664 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $50,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TEVA. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Monday. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Finally, Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $13.61 on Friday. The business has a 50 day moving average price of $15.51 and a 200 day moving average price of $17.70. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a market capitalization of $15.43 billion, a P/E ratio of -9.38, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.